Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Portage Biotech Inc (PRTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRTG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $140
1 Year Target Price $140
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.16% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.58M USD | Price to earnings Ratio - | 1Y Target Price 140 |
Price to earnings Ratio - | 1Y Target Price 140 | ||
Volume (30-day avg) 1 | Beta 0.67 | 52 Weeks Range 2.10 - 15.82 | Updated Date 06/30/2025 |
52 Weeks Range 2.10 - 15.82 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -68.17 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.45% | Return on Equity (TTM) -198.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11296377 | Price to Sales(TTM) - |
Enterprise Value 11296377 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.02 | Shares Outstanding 2270450 | Shares Floating 551729 |
Shares Outstanding 2270450 | Shares Floating 551729 | ||
Percent Insiders 37.23 | Percent Institutions 4.66 |
Analyst Ratings
Rating 1 | Target Price 140 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Portage Biotech Inc
Company Overview
History and Background
Portage Biotech Inc. was founded to advance innovative therapies in immuno-oncology. The company focuses on developing and commercializing novel platforms and product candidates to improve patient outcomes.
Core Business Areas
- Immuno-Oncology Platform: Developing novel immunotherapies to enhance the body's immune response to cancer.
- Drug Development: Identifying and developing promising drug candidates for various cancer types.
Leadership and Structure
The leadership team consists of experienced executives in the biotech and pharmaceutical industries. The organizational structure involves research and development, clinical operations, and business development divisions.
Top Products and Market Share
Key Offerings
- PORT-2: PORT-2 is a product of Portage Biotech Inc. Its purpose is the treatment of cancer. Its current status in Phase 1/2a clinical trial. Market share for PORT-2 is not yet applicable as the drug is in clinical trials. Competitors depend on the specific indication, however, generally speaking, competitors include major pharmaceutical companies and other biotech firms developing immunotherapies, such as Merck (MRK) with Keytruda, Bristol Myers Squibb (BMY) with Opdivo, and Roche (ROG.SW) with Tecentriq.
Market Dynamics
Industry Overview
The immuno-oncology industry is experiencing significant growth due to advancements in understanding the immune system's role in cancer and the development of novel therapies. The market is competitive, with numerous companies developing immunotherapies.
Positioning
Portage Biotech Inc. is positioned as a company focused on developing innovative immunotherapies, aiming to address unmet needs in cancer treatment. Its competitive advantage lies in its novel platforms and product candidates.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is substantial, projected to reach hundreds of billions of dollars in the coming years. Portage Biotech Inc. is positioned to capture a portion of this market through successful development and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology platforms
- Experienced leadership team
- Promising drug candidates in development
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early-stage drug development risks
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline through acquisitions or licensing
- Positive clinical trial results driving market adoption
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ROG.SW
Competitive Landscape
Portage Biotech Inc. faces intense competition from larger, more established pharmaceutical companies. To succeed, Portage Biotech Inc. will need to differentiate itself through its novel technologies.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on advancing drugs into clinical trials. Historical growth data is limited.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst estimates are not readily available.
Recent Initiatives: Focusing on clinical development and building partnerships.
Summary
Portage Biotech is an early-stage company focused on immuno-oncology with promising platforms. Its success hinges on successful clinical trials and partnerships. It faces stiff competition and financial limitations but has the potential for significant growth if its technologies prove effective. The company must effectively navigate regulatory hurdles and secure sufficient funding for development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Portage Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-25 | CEO & Director Mr. Alexander Pickett | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.portagebiotech.com |
Full time employees 7 | Website https://www.portagebiotech.com | ||
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.